All In Biotech

Drug Trial Radar · NCT05017987

Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012

A Phase I Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012 in Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: Jan 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Jun 19, 2021

Primary completion

Jul 12, 2021

Study completion Jul 12, 2021

Sponsor

Lead sponsor
AutotelicbioIndustry
Sponsor type
Industry
First posted
Aug 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To compare and evaluate safety and pharmacokinetic Characteristics after administration of ATB-101 or co-administration of ATB-1011 and ATB-1012 in fasted Healthy Adult Volunteers

Conditions

  • Healthy Adult Volunteers

Interventions

  • ATB-101, ATB-1011, ATB-1012Drug

    1. Test drug \- Code name: ATB-101 2. Control drug1 * Code name: ATB-1011 * Active ingredient: Olmesartan 3. Control drug2 * Code name: ATB-1012 * Active ingredient: Dapagliflozin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUCt of OlmesartanTime frame: Day1(first stage), Day8(scond stage)
  2. Cmax of OlmesartanTime frame: Day1(first stage), Day8(scond stage)
  3. AUCt of DapagliflozinTime frame: Day1(first stage), Day8(scond stage)
  4. Cmax of DapagliflozinTime frame: Day1(first stage), Day8(scond stage)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • H Plus Yangji Hospital

    Seoul, Gwanak-gu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.